Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1073MR)

This product GTTS-WQ1073MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1073MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13401MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ5440MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ2096MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ14855MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ2213MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ8769MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ4759MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ862MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW